China is no longer just a biotech market. It is increasingly a source of licensable innovation for global pharma.

Sanofi’s up-to-$1.53B rovadicitinib deal is the latest signal — and part of a much bigger shift in where drug innovation begins.

https://biotech.industryexaminer.com/sanofi-china-biotech-licensing-global-innovation/

#Biotech #Pharma #ChinaBiotech #DrugDevelopment #BiotechNews #TechNews